metformin · Glucophage

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (327)
Type 2 Diabetes
NCT07057479 · Eurofarma Laboratorios S.A.
2026-09 – 2028-02 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06083675 · Novo Nordisk A/S
2024-01-26 – 2027-05-28 · Diabetes Mellitus, Type 2
What this study did
NCT07093476 · Celltrion
2025-07-18 – 2027-04 · T2DM, Diabete Type 2, DM
What this study did
NCT06257966 · Beijing Dongfang Biotech Co., Ltd.
2024-07-17 – 2026-11-30 · Type2 Diabetes Mellitus
What this study did
NCT07026968 · CSPC Ouyi Pharmaceutical Co., Ltd.
2025-06-20 – 2026-11-13 · Type 2 Diabetes
What this study did
NCT06339086 · Chengdu Brilliant Pharmaceutical Co., Ltd.
2024-04 – 2025-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT05280496 · Tufts Medical Center
2022-06-01 – 2025-04-18 · Diabetes, Gestational, PreDiabetes, Diabetes Mellitus, Type 2
What this study did
NCT06952231 · University of Lahore
2024-05-21 – 2025-01-05 · Diabetes Mellitus
What this study did
NCT04271189 · Azienda Ospedaliero-Universitaria di Parma
2020-09-01 – 2024-12-31 · Newly Diagnosed Type 2 Diabetes
What this study did
NCT06107153 · University of Basrah
2023-11-01 – 2024-11-01 · Type2diabetes
What this study did
NCT05680129 · Hangzhou Sciwind Biosciences Co., Ltd.
2023-01-10 – 2024-10-12 · T2DM, Type 2 Diabetes Mellitus
What this study did
NCT04854512 · Anji Pharma
2021-05-18 – 2024-06-30 · Diabetes Mellitus, Type 2
What this study did
NCT05545800 · Xiangya Hospital of Central South University
2022-09-01 – 2024-06-01 · Type 2 Diabetes Mellitus
What this study did
NCT04841096 · Laboratorios Silanes S.A. de C.V.
2023-03-21 – 2024-05-15 · Type 2 Diabetes
What this study did
NCT05296044 · Jeil Pharmaceutical Co., Ltd.
2022-04-05 – 2024-02-28 · Type 2 Diabetes Mellitus
What this study did
NCT05688332 · University of Zambia
2023-08 – 2024-01 · Diabetes Mellitus Type 2 Without Complication
What this study did
NCT05413369 · Sanofi
2022-07-07 – 2023-10-20 · Type 2 Diabetes Mellitus
What this study did
NCT03862716 · Population Health Research Institute
2019-04-23 – 2023-07-31 · Type 2 Diabetes Mellitus
What this study did
NCT05629806 · Nanjing First Hospital, Nanjing Medical University
2022-04-10 – 2023-05-31 · Type 2 Diabetes, Blood Glucose Fluctuation
What this study did
NCT04504396 · PegBio Co., Ltd.
2020-06-23 – 2023-05-26 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05591235 · Nanjing First Hospital, Nanjing Medical University
2022-11 – 2023-02 · Type2diabetes, Insulin Resistance
What this study did
NCT04667143 · Jiangsu HengRui Medicine Co., Ltd.
2021-01 – 2022-10 · Diabetes Mellitus, Type II
What this study did
NCT05159882 · Newsoara Biopharma Co., Ltd.
2021-04-15 – 2022-09-30 · T2DM
What this study did
NCT02932475 · University of North Carolina, Chapel Hill
2017-05-25 – 2022-06-15 · Diabetes, Pregnancy
What this study did
NCT05801627 · Shenzhen Salubris Pharmaceuticals Co., Ltd.
2020-05-06 – 2022-05-24 · Diabetes Mellitus, Type 2
What this study did
NCT04373967 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2020-04-29 – 2021-12-02 · Type 2 Diabetes
What this study did
NCT03610412 · Coordinación de Investigación en Salud, Mexico
2019-08-01 – 2021-08-18 · Diabetes Mellitus, Type 2
What this study did
NCT04943692 · Laboratorios Silanes S.A. de C.V.
2021-08 – 2021-08 · Type 2 Diabetes
What this study did
NCT05360147 · Third Military Medical University
2021-01-20 – 2021-05-10 · Type 2 Diabetes Mellitus
What this study did
NCT03684642 · Sanofi
2018-09-26 – 2020-11-17 · Type 2 Diabetes Mellitus
What this study did
NCT03130426 · Population Health Research Institute
2017-06-27 – 2020-09-30 · Type 2 Diabetes Mellitus
What this study did
NCT02192424 · Mount Sinai Hospital, Canada
2014-07 – 2020-09 · Type 2 Diabetes
What this study did
NCT04390295 · Jiangsu HengRui Medicine Co., Ltd.
2017-11-02 – 2020-05 · Type 2 Diabetes Mellitus
What this study did
NCT03421119 · Cinnagen
2019-06-20 – 2019-12-01 · Diabetes Mellitus, Type 2
What this study did
NCT02623998 · Population Health Research Institute
2016-07-09 – 2019-11-30 · Type 2 Diabetes Mellitus
What this study did
NCT03529123 · Sanofi
2018-06-19 – 2019-11-25 · Type 2 Diabetes Mellitus
What this study did
NCT01779362 · RISE Study Group
2013-04 – 2019-08 · Prediabetes, Type 2 Diabetes
What this study did
NCT01234649 · Woman's
2011-08-11 – 2019-06-14 · Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
What this study did
NCT01353391 · Mount Sinai Hospital, Canada
2011-05-25 – 2019-06-05 · Type 2 Diabetes
What this study did
NCT02752113 · Institut für Pharmakologie und Präventive Medizin
2016-04 – 2019-05 · Diabetes Mellitus Type 2
What this study did
NCT02926950 · Lexicon Pharmaceuticals
2016-11 – 2019-03-22 · Type 2 Diabetes Mellitus
What this study did
NCT03214380 · Eli Lilly and Company
2017-07-14 – 2019-03-13 · Type 2 Diabetes Mellitus
What this study did
NCT03268005 · Novo Nordisk A/S
2017-09-19 – 2019-01-29 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2/3 (63)
Type 2 Diabetes
NCT07033585 · Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
2026-06-15 – 2026-11-28 · Type 2 Diabetes
What this study did
NCT06080802 · October University for Modern Sciences and Arts
2023-11-01 – 2024-12-01 · Heart Failure With Preserved Ejection Fraction, Diabete Type 2
What this study did
NCT03968224 · Centro Medico Nacional Siglo XXI IMSS
2018-08-04 – 2024-07-31 · PreDiabetes, Obesity, Morbid, Diabetes Mellitus, Type 2
What this study did
NCT04998032 · Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
2021-10-12 – 2023-08-13 · Type2 Diabetes
What this study did
NCT02064881 · Laboratorios Silanes S.A. de C.V.
2015-10 – 2020-08 · Type 2 Diabetes
What this study did
NCT02786823 · All India Institute of Medical Sciences, Bhubaneswar
2017-05-01 – 2017-09-15 · Diabetes Mellitus, Type 2
What this study did
NCT03167918 · Liaoning University of Traditional Chinese Medicine
2014-07-21 – 2017-05-01 · Type 2 Diabetes Mellitus, Pulmonary Function
What this study did
NCT01855763 · Dow University of Health Sciences
2008-12 – 2013-12 · Gestational Diabetes, Type 2 Diabetes, Pregnancy
What this study did
NCT01318135 · Takeda
2009-01 – 2010-04 · Type 2 Diabetes Mellitus
What this study did
NCT00940472 · Laboratorios Silanes S.A. de C.V.
2009-03 – 2009-12 · Diabetes Type 2
What this study did
NCT01318109 · Takeda
2008-08 – 2009-04 · Type 2 Diabetes Mellitus
What this study did
NCT00622089 · DiObex
2008-01 – 2008-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT00268476 · Medical Research Council
2005-07-08 – 2030-12 · Prostate Cancer
What this study did
NCT07229651 · Tanta University
2025-11-10 – 2027-09-20 · Parkinson Disease
What this study did
NCT04098666 · Columbia University
2021-03-22 – 2027-04-30 · Mild Cognitive Impairment
What this study did
NCT07585396 · Kafrelsheikh University
2024-04-10 – 2026-07-11 · Polycystic Ovary Syndrome, Infertility
What this study did
NCT06896981 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-01-01 – 2026-02-28 · Polycystic Ovary Syndrome (PCOS) Women, Obesity
What this study did
NCT06142656 · October 6 University
2023-11-25 – 2026-02-01 · Poly Cystic Ovary Syndrome
What this study did
NCT05646199 · University of Hull
2025-03-01 – 2025-12-30 · Polycystic Ovary Syndrome
What this study did
NCT07092618 · AgelessRx
2024-12-17 – 2025-08 · Longevity, GLP-1, Geroscience, Aging
What this study did
NCT06728982 · Minia University
2024-05-01 – 2025-07-15 · Rectal Cancer Patients
What this study did
NCT03452267 · Wayne State University
2019-09-01 – 2025-06 · Insulin Sensitivity
What this study did
NCT05412056 · The University of Hong Kong
2022-06 – 2025-06 · Preterm Birth, Premature Obstetric Labor, Twin; Complicating Pregnancy, Pregnancy Complications, Pregnancy Preterm, Metformin, Drug Effect
What this study did
NCT06691542 · Assiut University
2024-11-14 – 2025-04 · Non-Genital Warts
What this study did
NCT06766201 · Postgraduate Institute of Dental Sciences Rohtak
2023-08-01 – 2025-01-01 · Apical Periodontitis
What this study did
NCT04409795 · Joslin Diabetes Center
2021-08-26 – 2024-12-31 · Type 1 Diabetes, Monogenic Diabetes
What this study did
NCT06181422 · Tanta University
2024-04 – 2024-06-09 · Sepsis
What this study did
NCT03355469 · Rutgers University
2017-08-07 – 2024-05-23 · Metabolic Syndrome
What this study did
NCT03479476 · University of California, Davis
2018-04-30 – 2024-05-22 · Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders
What this study did
NCT03507413 · Medical University of Vienna
2018-09-26 – 2024-05-01 · Abdominal Aortic Aneurysm
What this study did
NCT05373680 · Tanta University
2022-01-01 – 2024-04-01 · Renal Insufficiency, Chronic
What this study did
NCT02065687 · Gynecologic Oncology Group
2014-03-17 – 2023-09-13 · Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
What this study did
NCT04387630 · Mansoura University
2020-06-05 – 2023-05-01 · Breast Cancer
What this study did
NCT04500678 · University of Hawaii
2019-02-01 – 2022-12-31 · HIV/AIDS
What this study did
NCT05638893 · Tanta University
2021-02-01 – 2022-04-15 · Knee Osteoarthritis
What this study did
NCT04607252 · Fudan University
2021-01-11 – 2021-06-03 · Atypical Endometrial Hyperplasia
What this study did
NCT04879511 · Ain Shams University
2018-02-10 – 2021-01-29 · Effect of Change in T1DM Glycemic Control
What this study did
NCT03129113 · University College, London
2017-03-01 – 2020-11-06 · Hepatic Steatosis, HIV-1-infection
What this study did
NCT04852510 · Saudi German Hospital - Madinah
2019-02-01 – 2020-08-31 · Polycystic Ovary Syndrome (PCOS)
What this study did
NCT03056274 · Epsom and St Helier University Hospitals NHS Trust
2019-01 – 2019-09 · Intrahepatic Cholestases, Pregnancy Complications
What this study did
NCT03981861 · Children's Mercy Hospital Kansas City
2016-07-02 – 2019-06-05 · PCOS
What this study did
NCT01666665 · The University of Texas Medical Branch, Galveston
2012-11 – 2019-04-23 · Insulin Resistance, Hypermetabolism, Hyperglycemia
What this study did
NCT02882477 · Hadassah Medical Organization
2016-12 – 2018-12 · Diabetes Mellitus, Iron Metabolism Disorders, Gastroduodenal Ulcer, Optic Atrophy, Sensorineural Hearing Loss, Platelet Dysfunction
What this study did
NCT03204058 · Government Dental College and Research Institute, Bangalore
2016-02-10 – 2017-02-23 · Chronic Periodontitis
What this study did
NCT03204071 · Government Dental College and Research Institute, Bangalore
2016-02 – 2017-02 · Chronic Periodontitis
What this study did
NCT01690091 · Institute for Clinical and Experimental Medicine
2012-11 – 2016-12 · Insulin Resistance, Chronic Heart Failure
What this study did
NCT02802215 · Ain Shams University
2016-01 – 2016-09 · Polycystic Ovary Syndrome, Diabetes, Gestational
What this study did
NCT03207698 · Government Dental College and Research Institute, Bangalore
2015-09 – 2016-05 · Furcation Defects
What this study did
NCT01217307 · University Medical Center Groningen
2011-01 – 2015-10 · ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes
What this study did
NCT01273584 · Epsom and St Helier University Hospitals NHS Trust
2010-10 – 2015-09 · Pregnancy Complications, Obesity
What this study did
Phase 2 (345)
Type 2 Diabetes
NCT07139405 · Myopharm Limited
2026-09-01 – 2027-12-30 · Type 2 Diabetes (T2DM)
What this study did
NCT05833958 · George Medicines PTY Limited
2024-09 – 2025-09 · Type 2 Diabetes
What this study did
NCT03974139 · Lille Catholic University
2020-07-03 – 2024-09-30 · Obesity Without Type 2 Diabetes, With BMI>30
What this study did
NCT06125873 · Islamabad Medical and Dental College
2023-03-15 – 2024-08-01 · Diabetes Mellitus Type 2
What this study did
NCT05990205 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2018-04-17 – 2024-03-01 · PreDiabetes
What this study did
NCT03606694 · University of Guadalajara
2019-10-30 – 2023-12-30 · Type 2 Diabetes Mellitus
What this study did
NCT04209075 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2020-03-10 – 2021-07-15 · Diabetes
What this study did
NCT04626089 · Laboratorios Silanes S.A. de C.V.
2021-02 – 2021-02 · Severe Acute Respiratory Syndrome Coronavirus 2, Metabolic Syndrome, Type 2 Diabetes
What this study did
NCT03317028 · Center Laboratories, Inc.
2017-10-10 – 2020-04-21 · T2DM With Inadequate Glycemic Control
What this study did
NCT03751657 · Novo Nordisk A/S
2018-11-29 – 2020-01-17 · Diabetes Mellitus, Type 2
What this study did
NCT03416127 · University of Guadalajara
2018-01-30 – 2019-12-20 · Diabetes Mellitus, Type 2
What this study did
NCT03230786 · KeyBioscience AG
2017-08-23 – 2018-07-31 · Type 2 Diabetes Mellitus
What this study did
NCT02033876 · Mayo Clinic
2013-10 – 2017-03 · Type 2 Diabetes Mellitus
What this study did
NCT01425580 · Thomas Nystrom
2012-01 – 2016-08 · Congestive Heart Failure, Type 2 Diabetes Mellitus
What this study did
NCT02500628 · Woodinville Psychiatric Associates
2015-07 – 2016-02 · Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
What this study did
NCT02151461 · NuSirt Biopharma
2014-07 – 2016-01 · Type 2 Diabetes Mellitus
What this study did
NCT02435277 · NuSirt Biopharma
2014-10 – 2016-01 · Type 2 Diabetes Mellitus
What this study did
NCT02710448 · Centre Hospitalier Universitaire, Amiens
2012-06 – 2015-10 · Renal Disorder Associated With Type II Diabetes Mellitus
What this study did
NCT02274740 · Sanofi
2015-04 – 2015-08 · Type II Diabetes Mellitus
What this study did
NCT02053103 · Pfizer
2014-03 – 2014-04 · Type 2 Diabetes Mellitus
What this study did
NCT01929863 · GlaxoSmithKline
2013-08-01 – 2013-11-21 · Diabetes Mellitus, Type 2
What this study did
NCT01725126 · GlaxoSmithKline
2013-02-10 – 2013-09-12 · Obesity
What this study did
NCT01984489 · Jiangsu HengRui Medicine Co., Ltd.
2012-06 – 2013-08 · Type 2 Diabetes
What this study did
NCT01514149 · ConjuChem
2011-09 – 2013-03 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01969318 · Jiangsu HengRui Medicine Co., Ltd.
2012-03 – 2012-11 · Type 2 Diabetes
What this study did
NCT00701935 · AstraZeneca
2008-08 – 2012-01 · Diabetes Mellitus
What this study did
NCT01240759 · Shionogi
2010-10 – 2012-01 · Type 2 Diabetes Mellitus
What this study did
NCT01117584 · Astellas Pharma Inc
2010-04-06 – 2011-04-01 · Type 2 Diabetes Mellitus
What this study did
NCT00971243 · Tanabe Pharma Corporation
2009-08 – 2011-04 · Type 2 Diabetes Mellitus
What this study did
NCT00995345 · ActivX Biosciences, Inc.
2009-10 – 2011-01 · Type 2 Diabetes
What this study did
NCT01111955 · Bristol-Myers Squibb
2010-07 – 2011-01 · Diabetes Mellitus, Type 2
What this study did
NCT01175473 · Sanofi
2010-08 – 2010-11 · Type 2 Diabetes Mellitus
What this study did
NCT00443755 · Mayo Clinic
2005-08 – 2010-08 · Type 2 Diabetes, Insulin Resistance, Metabolic Syndrome
What this study did
NCT00868790 · Merck Sharp & Dohme LLC
2009-03-24 – 2010-07-13 · Type 2 Diabetes Mellitus
What this study did
NCT00792935 · Merck Sharp & Dohme LLC
2009-01 – 2010-02 · Type 2 Diabetes Mellitus
What this study did
NCT00743002 · OPKO Health, Inc.
2008-08 – 2009-12 · Diabetes Mellitus, Type 2
What this study did
NCT00789035 · Boehringer Ingelheim
2008-10 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
NCT00871936 · Response Pharmaceuticals
2009-04 – 2009-10 · Type 2 Diabetes
What this study did
NCT00823680 · Hoffmann-La Roche
2009-04 – 2009-08 · Diabetes Mellitus Type 2
What this study did
NCT00698230 · Incyte Corporation
2008-05 – 2009-05 · Type 2 Diabetes
What this study did
NCT00940797 · Laboratorios Silanes S.A. de C.V.
2008-07 – 2009-02 · Diabetes Type 2
What this study did
NCT00631488 · Merck Sharp & Dohme LLC
2008-02 – 2009-01 · Diabetes Mellitus, Type 2
What this study did
NCT00494663 · DiObex
2007-07 – 2008-12 · Type 2 Diabetes
What this study did
Phase 1/2 (44)
Type 2 Diabetes
NCT03686657 · ARKAY Therapeutics
2026-12-10 – 2031-01-31 · Type 2 Diabetes, High Blood Pressure, Arthritis, Obesity
What this study did
NCT01786707 · Rodolfo Alejandro
2009-07 – 2013-03 · Type 2 Diabetes Mellitus
What this study did
NCT01677299 · Elcelyx Therapeutics, Inc.
2012-05 – 2012-09 · Type 2 Diabetes Mellitus
What this study did
NCT01396564 · Coordinación de Investigación en Salud, Mexico
2005-10 – 2011-07 · Type 2 Diabetes
What this study did
NCT01043965 · University of Sao Paulo General Hospital
2005-08 – 2009-08 · Type 2 Diabetes
What this study did
NCT00425009 · Shanghai Jiao Tong University School of Medicine
2004-01 – 2004-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT04536805 · Institut Cancerologie de l'Ouest
2020-11-17 – 2031-11 · Prostate Cancer
What this study did
NCT07129473 · University of Southern California
2026-07-13 – 2031-03 · Hyperemesis Gravidarum
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT05768139 · Eli Lilly and Company
2023-04-17 – 2030-07 · Breast Cancer, Solid Tumors, Adult
What this study did
NCT07666698 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2026-07-01 – 2029-09 · Heart Failure, Left Ventricular Assist Device
What this study did
NCT04545736 · National Eye Institute (NEI)
2020-11-23 – 2029-02-02 · ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
What this study did
NCT06030622 · State University of New York - Downstate Medical Center
2024-04-17 – 2028-12-30 · Pancreatic Cancer Metastatic
What this study did
NCT05036226 · Medical University of South Carolina
2022-03-03 – 2028-05-21 · Prostate Cancer Recurrent, Solid Tumor, Adult
What this study did
NCT06090227 · Yale University
2023-12-14 – 2027-11 · Focal Segmental Glomerulosclerosis
What this study did
NCT04121468 · The Hospital for Sick Children
2020-02-24 – 2027-10 · Multiple Sclerosis (MS)
What this study did
NCT01638676 · University of Louisville
2012-07 – 2027-06 · Melanoma
What this study did
NCT07395960 · Fudan University
2025-09-01 – 2026-09-30 · Mild Cognitive Impairment, Overweight or Obesity, Elderly
What this study did
NCT06871904 · Ziauddin University
2025-04-07 – 2025-12-30 · Oral Submucous Fibrosis
What this study did
NCT06845540 · University of Puerto Rico
2025-02-20 – 2025-05-30 · Melasma
What this study did
NCT05759312 · Fudan University
2023-03 – 2025-02 · Ovarian Clear Cell Carcinoma
What this study did
NCT06332612 · Ziauddin University
2024-08-12 – 2025-01-06 · Oral Submucous Fibrosis
What this study did
NCT04767841 · Sadat City University
2021-02-16 – 2024-12-31 · Osteo Arthritis Knee
What this study did
NCT04377451 · Oxford University Clinical Research Unit, Vietnam
2020-07-27 – 2023-08-01 · Dengue, Viral Infection, Metformin, Anti-inflammatory Agents, Obesity, Overweight
What this study did
NCT05215990 · Mahidol University
2022-01-15 – 2023-03-31 · Tuberculosis, Pulmonary
What this study did
NCT02949700 · Baylor College of Medicine
2017-01-26 – 2022-07-07 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04973891 · Shengjing Hospital
2021-04-07 – 2022-03-08 · Polycystic Ovary Syndrome
What this study did
NCT04530747 · Pennington Biomedical Research Center
2021-01-28 – 2021-11-30 · Sleep Apnea, Obstructive
What this study did
NCT04268563 · Shahid Beheshti University of Medical Sciences
2020-01-10 – 2021-07-30 · Polycystic Ovary Syndrome, Infertility, ART
What this study did
NCT04141163 · Rowan University
2019-10-29 – 2021-03 · Fragile X Syndrome
What this study did
NCT04068246 · Sadat City University
2019-08-01 – 2021-02-28 · Rheumatoid Arthritis
What this study did
NCT04088448 · Sadat City University
2017-01-01 – 2020-06-01 · Major Depressive Disorder
What this study did
NCT02755844 · Hospices Civils de Lyon
2016-09-23 – 2020-06 · Recurrent Endometrial Cancer
What this study did
NCT03772964 · Brian Zuckerbraun
2019-01-22 – 2020-03-31 · Inflammatory Response
What this study did
NCT02495103 · National Cancer Institute (NCI)
2015-08-26 – 2020-02-06 · Renal Cell Carcinoma, Hereditary Leiomyomatosis, Renal Cell Cancer
What this study did
NCT02496741 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2015-11 – 2019-11-18 · Glioma, Cholangiocarcinoma, Chondrosarcoma
What this study did
NCT03757923 · Dow University of Health Sciences
2018-06-18 – 2019-01 · Menstrual Irregularities, Hyperandrogenism
What this study did
NCT01804049 · VA Office of Research and Development
2014-04-08 – 2018-08-31 · Prediabetes
What this study did
NCT02143050 · University of Louisville
2014-09 – 2017-11-17 · Melanoma
What this study did
NCT01488552 · Pancreatic Cancer Research Team
2011-11 – 2016-08 · Stage IV Pancreatic Cancer
What this study did
NCT02179788 · Children's Hospital Medical Center, Cincinnati
2014-06 – 2016-07 · Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
What this study did
NCT01329016 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
2011-07 – 2015-02-28 · Gestational Diabetes Mellitus
What this study did
NCT00390273 · Centre de Recherche en Nutrition Humaine Rhone-Alpe
2006-12 – 2007-10 · Hyperlactatemia
What this study did
Phase 1 (475)
Type 2 Diabetes
NCT06120881 · University of California, San Francisco
2024-04-25 – 2026-12-31 · Type 2 Diabetes
What this study did
NCT07511010 · Chipscreen Biosciences, Ltd.
2026-09-10 – 2026-10-25 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT07872358 · Humanis Saglık Anonim Sirketi
2026-06-07 – 2026-10-07 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07691203 · Humanis Saglık Anonim Sirketi
2026-03-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
What this study did
NCT07694115 · Humanis Saglık Anonim Sirketi
2026-05-07 – 2026-07-01 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07372118 · Humanis Saglık Anonim Sirketi
2025-09-27 – 2026-01-07 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01762046 · Massachusetts General Hospital
2008-01 – 2025-12 · Diabetes Mellitus, Type 2
What this study did
NCT07034781 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT07044765 · AJU Pharm Co., Ltd.
2025-08 – 2025-11 · Type2 Diabetes Mellitus
What this study did
NCT07266766 · Humanis Saglık Anonim Sirketi
2025-08-05 – 2025-10-06 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07213895 · Humanis Saglık Anonim Sirketi
2025-05-21 – 2025-09-18 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06723691 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-12-18 – 2025-06-09 · Type 2 Diabetes
What this study did
NCT06670209 · Gan and Lee Pharmaceuticals, USA
2024-10-30 – 2025-03-19 · Type 2 Diabetes
What this study did
NCT06654960 · Fujian Shengdi Pharmaceutical Co., Ltd.
2024-11-05 – 2024-12-26 · Type 2 Diabetes
What this study did
NCT03816488 · McMaster University
2023-12-01 – 2024-12-01 · Diabetes Mellitus, Type 2, Hyperglycemia, Perioperative/Postoperative Complications, Salsalate to Improve Non-cardiac Surgery Glucose Control
What this study did
NCT05760677 · Affiliated Hospital of Nantong University
2022-10-01 – 2024-09-30 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D
What this study did
NCT06483243 · Chong Kun Dang Pharmaceutical
2024-04-04 – 2024-05-17 · Type 2 Diabetes Mellitus
What this study did
NCT07948473 · The Affiliated Hospital Of Guizhou Medical University
2024-03-18 – 2024-05-17 · Diabetes Mellitus Type 2
What this study did
NCT06247748 · Beijing Dongfang Biotech Co., Ltd.
2023-10-19 – 2024-04-15 · Diabetes Mellitus, Type 2, Overweight
What this study did
NCT06450262 · Humanis Saglık Anonim Sirketi
2024-01-04 – 2024-03-05 · Type2diabetes
What this study did
NCT07072949 · University of Banja Luka
2023-01-03 – 2024-01-31 · Type 2 Diabetes Mellitus
What this study did
NCT05262257 · The First Affiliated Hospital with Nanjing Medical University
2022-04-01 – 2023-12-30 · Type2 Diabetes
What this study did
NCT06204107 · Chong Kun Dang Pharmaceutical
2023-11-21 – 2023-12-06 · Type 2 Diabetes Mellitus
What this study did
NCT04504045 · University of Southern Denmark
2020-09-01 – 2022-05-10 · Diabetes Mellitus, Type 2
What this study did
NCT05108350 · Shandong Suncadia Medicine Co., Ltd.
2021-11-09 – 2021-12-10 · Type II Diabetes
What this study did
NCT03445702 · St. Louis University
2018-10-15 – 2020-10-27 · Diabetes Mellitus, Type 2, Metformin Adverse Reaction
What this study did
NCT04065581 · Bayer
2019-10-14 – 2020-03-06 · Diabetes Mellitus, Type 2
What this study did
NCT02803918 · Sanofi
2017-05-17 – 2020-01-27 · Type 2 Diabetes Mellitus
What this study did
NCT04070794 · LG Chem
2019-11-01 – 2019-12-30 · Type2 Diabetes
What this study did
NCT06084156 · Haisco Pharmaceutical Group Co., Ltd.
2019-08-10 – 2019-12-09 · Type 2 Diabetes Mellitus
What this study did
NCT04050098 · LG Chem
2019-11-01 – 2019-11-30 · Type2 Diabetes
What this study did
NCT05549583 · Galenicum Health
2018-04-15 – 2018-04-25 · Bioequivalence, Type 2 Diabetes
What this study did
NCT03686722 · Mohamed Raslan
2017-09-09 – 2017-12-06 · Diabetes Mellitus, Type 2, Hepatitis C, Drug Interactions
What this study did
NCT05549570 · Galenicum Health
2017-10-22 – 2017-11-01 · Bioequivalence, Diabetes Mellitus, Type 2
What this study did
NCT03061981 · Dong-A ST Co., Ltd.
2017-03-29 – 2017-10-11 · Diabetes Mellitus, Type 2
What this study did
NCT02844803 · Namyi Gu
2016-07 – 2017-06 · Diabetes Mellitus
What this study did
NCT03310749 · Stendhal Americas, S.A.
2016-01-15 – 2016-05-03 · Diabetes Mellitus, Type 2
What this study did
NCT02685774 · Chong Kun Dang Pharmaceutical
2016-02 – 2016-04 · Diabetes Mellitus, Type II
What this study did
NCT02366377 · Jiangsu HengRui Medicine Co., Ltd.
2015-02 – 2016-03 · Type 2 Diabetes Mellitus
What this study did
Phase 4 (400)
Type 2 Diabetes
NCT07771010 · University Medical Centre Ljubljana
2026-04-16 – 2028-07-31 · Diabetes Type 2
What this study did
NCT07244003 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-03-29 – 2028-06-30 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT07939750 · Allied Hospital Faisalabad
2026-12-01 – 2028-01-31 · Type 2 Diabetes Mellitus (DM)
What this study did
NCT07173712 · Yanbing Li
2026-03-15 – 2027-12-31 · Type 2 Diabetes
What this study did
NCT06682351 · Stanford University
2024-11 – 2027-12 · Prediabetes / Type 2 Diabetes
What this study did
NCT07323381 · Bin Lu
2025-12-30 – 2027-09-30 · Diabetes Type 2
What this study did
NCT07442006 · JW Pharmaceutical
2025-10-29 – 2027-03-31 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06417489 · Peking University First Hospital
2024-05-31 – 2026-12-31 · Type 2 Diabetes
What this study did
NCT07165158 · The First Affiliated Hospital of Xiamen University
2025-09-15 – 2026-12-31 · Osteoporosis, Osteoporosis Fracture, T2DM
What this study did
NCT07019012 · Huazhong University of Science and Technology
2025-07-30 – 2026-12-30 · T2DM
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT06862739 · Nabiqasim Industries (Pvt) Ltd
2025-10-30 – 2026-06-30 · Diabetes Mellitus, Type 2 DM
What this study did
NCT07452913 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06296836 · University of Illinois at Chicago
2025-01-21 – 2026-04-30 · Diabetes Mellitus, Type 2
What this study did
NCT06439758 · King Saud University
2024-08-01 – 2025-12-01 · Diabetes Type 2, Osteoporosis
What this study did
NCT07531108 · Hawler Medical University
2024-11-15 – 2025-11-27 · Diabetes Mellitus, Type 2
What this study did
NCT06327815 · AstraZeneca
2024-03-15 – 2025-06-30 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT06759922 · Bahria University
2025-01-01 – 2025-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06860841 · Campus Bio-Medico University
2025-01-10 – 2025-04-10 · Type 2 Diabetes, Overweight and Obese Adults
What this study did
NCT07077525 · Al-Azhar University
2023-06-01 – 2024-08-31 · Type 2 Diabetes
What this study did
NCT04298684 · Centre Hospitalier Universitaire de la Guadeloupe
2021-01-01 – 2024-07-01 · Diabetes Mellitus, Type 2, Thyroid Nodule (Benign)
What this study did
NCT05440591 · Tan Tock Seng Hospital
2019-04-01 – 2023-05-10 · Diabetes
What this study did
NCT01107717 · The University of Texas Health Science Center at San Antonio
2009-01 – 2023-02-03 · Diabetes
What this study did
NCT02571608 · McMaster University
2022-01-01 – 2022-12-31 · Diabetes Mellitus Type 2
What this study did
NCT02621489 · Karolinska Institutet
2015-12 – 2022-10 · Atherosclerosis, Diabetes, Restenosis
What this study did
NCT05167513 · Getz Pharma
2021-01-01 – 2022-04-28 · Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin
What this study did
NCT02338921 · Seoul National University Bundang Hospital
2015-01 – 2021-12-31 · Type 2 Diabetes
What this study did
NCT04653779 · Dong-A ST Co., Ltd.
2020-12 – 2021-07 · Diabetes Mellitus, Type 2, Renal Disease, Diabetes Mellitus, Metabolic Disease, Endocrine System Diseases
What this study did
NCT04392557 · University of Catanzaro
2020-07-01 – 2021-06-20 · Diabetes Mellitus, Type 2
What this study did
NCT04284722 · Kepler University Hospital
2020-02 – 2021-04 · Hyperglycemia, Metformin, Type 2 Diabetes, Hyperlactatemia
What this study did
NCT04287387 · Peking Union Medical College Hospital
2020-03-02 – 2021-03-02 · Type2 Diabetes Mellitus
What this study did
NCT01001962 · Aristotle University Of Thessaloniki
2016-01 – 2020-01 · Hypertension, Type II Diabetes
What this study did
NCT02409238 · SingHealth Polyclinics
2015-03-11 – 2019-12-31 · Mild Cognitive Impairment, Insulin Resistance, Diabetes Mellitus, Type 2
What this study did
NCT03982238 · Majianhua
2019-06-15 – 2019-12-31 · Type 2 Diabetes
What this study did
NCT02535299 · Third Military Medical University
2016-06 – 2019-12 · GLP-1;Metformin;Telomere-telomerase System;Par-4
What this study did
NCT04707508 · Nantou Christian Hospital
2017-12-01 – 2019-11-29 · Diabetes Mellitus, Type 2
What this study did
NCT03819790 · LMC Diabetes & Endocrinology Ltd.
2018-10-02 – 2019-11-19 · Diabetes Mellitus, Type 2
What this study did
NCT03693560 · Damanhour University
2018-10-08 – 2019-10-10 · Coronary Artery Disease, Diabetes Mellitus, Type 2
What this study did
NCT01528254 · Novartis Pharmaceuticals
2012-03-30 – 2019-04-04 · Type 2 Diabetes Mellitus
What this study did
NCT02561130 · Population Health Research Institute
2015-12 – 2018-12-31 · Type 2 Diabetes Mellitus
What this study did
NCT03196362 · Sun Yat-sen University
2016-12-01 – 2018-12-31 · Type 2 Diabetes Mellitus
What this study did
NCT03118713 · Astellas Pharma Korea, Inc.
2017-04-25 – 2018-12-12 · Type 2 Diabetes Mellitus
What this study did
NCT01471808 · Sun Yat-sen University
2011-10 – 2018-12 · Diabetes Mellitus, Type 2
What this study did
NCT03039075 · Chongqing Medical University
2016-11 – 2018-11 · Diabetes Mellitus
What this study did
Early phase / not applicable (272)
Type 2 Diabetes
NCT07768280 · Jiangxi University of Traditional Chinese Medicine
2026-09 – 2028-03 · Type 2 Diabetes Mellitus
What this study did
NCT07778719 · The 95th Hospital of Putian,Putian, Fujian, China
2026-10-01 – 2027-12-11 · Type 2 Diabetes, Metabolic Dysfunction-Associated Steatotic Liver Disease
What this study did
NCT02969798 · The University of Texas Health Science Center at San Antonio
2014-01-01 – 2027-07 · Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
What this study did
NCT06846138 · Pauls Stradins Clinical University Hospital
2025-03-01 – 2026-12-01 · Diabetes Mellitus Type 2
What this study did
NCT02087826 · Massachusetts General Hospital
2014-04 – 2026-12 · Genetics, Metabolism, Type 2 Diabetes
What this study did
NCT07303556 · Nazarbayev University
2024-12-18 – 2026-11-01 · Heart Failure, Diabete Type 2, Arterial Hypertension
What this study did
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT06863532 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-30 – 2026-09-01 · Type 2 Diabetes
What this study did
NCT07519265 · Chipscreen Biosciences, Ltd.
2026-07-09 – 2026-08-03 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT07412015 · Chipscreen Biosciences, Ltd.
2026-05-15 – 2026-05-28 · T2DM (Type 2 Diabetes Mellitus)
What this study did
NCT04088851 · German Diabetes Center
2019-09-11 – 2025-12-31 · Type 2 Diabetes
What this study did
NCT06983223 · Liaquat University of Medical & Health Sciences
2025-08-15 – 2025-12-03 · Vitamin B 12 Deficiency, Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT07176338 · Vienna Institute for Research in Ocular Surgery
2022-10-12 – 2025-10-01 · Cataract, Diabetes Mellitus Type 2
What this study did
NCT07338331 · Galala University
2023-04-04 – 2025-09-19 · Diabete Type 2, Non Alcoholic Fatty Liver
What this study did
NCT07172269 · Mais Qais Hbeeb
2024-09-15 – 2025-05-26 · Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus, Insulin Resistance
What this study did
NCT04018105 · University Hospital, Lille
2021-07-28 – 2025-04-05 · Impaired Glucose Tolerance, Type2 Diabetes
What this study did
NCT05779644 · RenJi Hospital
2023-02-23 – 2025-02-23 · Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose, Metabolism Disorder, Lipid
What this study did
NCT03558867 · Garvan Institute of Medical Research
2018-06-05 – 2024-07-23 · Pre Diabetes, Type 2 Diabetes Mellitus
What this study did
NCT05939921 · Diabetes Foundation, India
2022-05-01 – 2023-06-30 · Type2diabetes
What this study did
NCT03194009 · Instituto Nacional de Salud Publica, Mexico
2017-08-10 – 2022-12-31 · Diabetes Mellitus, Type 2, Prediabetic State
What this study did
NCT05041673 · Alexandria University
2021-02-23 – 2022-09-30 · Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
What this study did
NCT04639492 · Microbio Co Ltd
2020-11-02 – 2022-09-23 · Type-II Diabetes
What this study did
NCT04053621 · Laboratorios Manuell SA
2021-01 – 2022-03 · Diabetes Mellitus, Type 2
What this study did
NCT04089280 · Medical University of Silesia
2018-10-16 – 2021-12-31 · Diabetes Mellitus, Type 2, Metformin Adverse Reaction
What this study did
NCT03961659 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2019-05 – 2021-02 · Type 2 Diabetes Mellitus, Obesity, Cognitive Impairment
What this study did
NCT03907423 · Rehab Werida
2019-04-01 – 2021-01-31 · Diabetes Mellitus, Type 2
What this study did
NCT05004948 · Prince Sattam Bin Abdulaziz University
2019-01-01 – 2019-10-15 · Type 2 Diabetes
What this study did
NCT04120259 · Ziauddin University
2019-04-22 – 2019-08-26 · Diabetes Mellitus, Type 2
What this study did
NCT02846233 · University of California, San Francisco
2016-08 – 2018-12 · Type 2 Diabetes Mellitus
What this study did
NCT03316690 · Kristian Karstoft
2017-10-20 – 2018-10-01 · Impaired Glucose Tolerance, Diabetes Mellitus, Type 2
What this study did
NCT03329651 · Kristian Karstoft
2017-11-10 – 2018-10-01 · Impaired Glucose Tolerance, Diabetes Mellitus, Type 2
What this study did
NCT02694289 · Maya Guglin
2016-11 – 2018-09-10 · Type 2 Diabetes Mellitus
What this study did
NCT02693392 · All India Institute of Medical Sciences, Bhubaneswar
2016-01-17 – 2018-08-16 · Type-2 Diabetes Mellitus
What this study did
NCT03189732 · Charles University, Czech Republic
2015-10-01 – 2018-01 · Diabetes Mellitus, Type 2
What this study did
NCT02548741 · University of Arizona
2015-09 – 2017-08 · Type 2 Diabetes Mellitus
What this study did
NCT02951260 · Copenhagen University Hospital, Rigshospitalet
2016-10 – 2017-07 · Diabetes Mellitus, Type 2
What this study did
NCT03165877 · Universidad de Valparaiso
2016-05-31 – 2016-10-13 · Diabetes Mellitus, Type 2
What this study did
NCT02497313 · University Hospital, Gentofte, Copenhagen
2015-07 – 2016-07 · Diabetes Mellitus, Type 2
What this study did
NCT03189407 · Titilayo O Fakeye
2016-03-01 – 2016-04-30 · Type 2 Diabetes Mellitus
What this study did
NCT02026310 · Qifu Li
2014-01 – 2015-12 · Diabetes Mellitus, Type 2
What this study did
NCT02076347 · Ohio State University
2014-02 – 2015-10 · Type 2 Diabetes, Vitamin B12 Deficiency, Neuropathy, Anemia
What this study did
NCT02798172 · Fourth People's Hospital of Shenyang
2014-05 – 2015-08 · Diabetes Mellitus, Type 2
What this study did
NCT02135549 · Boston Therapeutics
2014-05 – 2014-10 · Type 2 Diabetes Mellitus
What this study did
NCT01771185 · University of Sao Paulo
2012-10 – 2013-12 · Type 2 Diabetes
What this study did
NCT01334684 · Casa Sollievo della Sofferenza IRCCS
2011-05 – 2013-09 · Type 2 Diabetes
What this study did
NCT01963663 · Tehran University of Medical Sciences
2012-11 – 2013-04 · Type 2 Diabetes Mellitus
What this study did
NCT00978263 · Chongqing Medical University
2009-02 – 2012-06 · Diabetes
What this study did
NCT02027103 · Tehran University of Medical Sciences
2012-01 – 2012-04 · Type 2 Diabetes Mellitus
What this study did
NCT01561976 · GlaxoSmithKline
2012-01-30 – 2012-02-21 · Diabetes Mellitus, Type 2
What this study did
Used as active comparator (198)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (46)
Type 2 Diabetes
NCT06246799 · The University of Texas Health Science Center at San Antonio
2024-11-07 – 2029-06-30 · Type 2 Diabetes (Adult Onset)
What this study did
NCT06560333 · Eurofarma Laboratorios S.A.
2026-11-30 – 2029-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT03925714 · Sherief Abd-Elsalam
2019-04-01 – 2028-12 · DM
What this study did
NCT04670666 · EMS
2024-11-18 – 2027-06 · Type 2 Diabetes Mellitus
What this study did
NCT05098470 · University of Alabama at Birmingham
2022-03-07 – 2026-07-29 · Type 2 Diabetes
What this study did
NCT05345327 · The George Institute
2023-01-01 – 2026-06-30 · Type 2 Diabetes
What this study did
NCT07279909 · Hamdard University
2024-03-09 – 2026-05-20 · Diabetes Type 2, Diabetes Mellitus, Experimental, HbA1c, Urinary Glucose, Ability of Experimental Drug to Lower HbA1c Compare to Metformin
What this study did
NCT06140485 · Natural Wellness Egypt
2024-03 – 2025-10 · Diabetes Mellitus, Type 2
What this study did
NCT05760456 · Centre of Clinical Pharmacology, Hanoi Medical University
2023-03-15 – 2024-08-31 · Type 2 Diabetes
What this study did
NCT01485614 · Merck Sharp & Dohme LLC
2012-02-10 – 2019-10-09 · Diabetes Mellitus, Type 2 Diabetes
What this study did
NCT03066830 · Lexicon Pharmaceuticals
2017-02-24 – 2019-04-30 · Type 2 Diabetes Mellitus
What this study did
NCT05451147 · A & U Tibbia College Karol Bagh
2018-09-03 – 2019-04-30 · Diabetes Mellitus, Type 2
What this study did
NCT02827903 · Jeil Pharmaceutical Co., Ltd.
2016-01-15 – 2018-03-16 · Type 2 Diabetes, Dyslipidemia
What this study did
NCT01755468 · Mount Sinai Hospital, Canada
2013-04 – 2017-10 · Type 2 Diabetes
What this study did
NCT02586129 · Yuhan Corporation
2015-11-04 – 2017-07-07 · Dyslipidemia, Type II Diabetes
What this study did
NCT01890122 · Takeda
2013-09 – 2015-10 · Diabetes Mellitus
What this study did
NCT01717313 · Merck Sharp & Dohme LLC
2012-12-05 – 2015-06-19 · Type 2 Diabetes Mellitus
What this study did
NCT01555164 · Gilead Sciences
2012-06 – 2013-10 · Type 2 Diabetes Mellitus
What this study did
NCT01368081 · Boehringer Ingelheim
2011-05 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01076088 · Merck Sharp & Dohme LLC
2010-11-15 – 2012-12-24 · Type 2 Diabetes Mellitus
What this study did
NCT01370707 · HK inno.N Corporation
2011-04 – 2012-07 · Diabetes Mellitus
What this study did
NCT01126580 · Eli Lilly and Company
2010-05 – 2012-06 · Diabetes Mellitus, Type 2
What this study did
NCT01204294 · Boehringer Ingelheim
2010-09 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT01023581 · Takeda
2009-11 – 2011-06 · Diabetes Mellitus, Type 2
What this study did
NCT00798161 · Boehringer Ingelheim
2008-12 – 2010-05 · Diabetes Mellitus, Type 2
What this study did
NCT00859898 · AstraZeneca
2009-04 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
NCT00121641 · AstraZeneca
2005-07 – 2010-02 · Diabetes Mellitus, Type 2
What this study did
NCT00374907 · AstraZeneca
2006-09 – 2009-12 · Type 2 Diabetes
What this study did
NCT00754689 · Sanofi
2008-09 – 2008-11 · Diabetes Mellitus, Type 2
What this study did
NCT00727857 · Takeda
2007-06 – 2008-08 · Diabetes Mellitus
What this study did
NCT00449930 · Merck Sharp & Dohme LLC
2007-03-01 – 2008-07-25 · Type 2 Diabetes Mellitus
What this study did
NCT00382096 · Novartis Pharmaceuticals
2006-09 – 2008-06-03 · Diabetes Mellitus, Type 2
What this study did
NCT00396357 · Novartis Pharmaceuticals
2006-10 – 2008-06 · Diabetes Mellitus, Type 2
What this study did
NCT00383578 · Novartis Pharmaceuticals
2006-09 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
NCT00469586 · Novo Nordisk A/S
2007-04-26 – 2008-04-24 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT00099866 · Novartis Pharmaceuticals
2004-01 – 2005-08 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03925701 · Sherief Abd-Elsalam
2019-04-01 – 2028-12 · dm
What this study did
NCT07937449 · Dexa Medica Group
2025-07-07 – 2026-10-15 · Prediabetes
What this study did
NCT05838573 · Central South University
2023-05-08 – 2026-06-08 · Schizophrenia
What this study did
NCT05965908 · Beni-Suef University
2024-08-01 – 2025-12-30 · Polycystic Ovary
What this study did
NCT01999686 · Dexa Medica Group
2014-10 – 2019-05 · Polycystic Ovary Syndrome (PCOS), Insulin Resistance
What this study did
NCT02338193 · Woman's
2015-09-22 – 2019-03-13 · Diabetes Prevention in Women After GDM Who Are at High-risk
What this study did
NCT02491333 · The First Affiliated Hospital of Guangzhou Medical University
2015-08 – 2018-10 · Polycystic Ovary Syndrome, Insulin Resistance
What this study did
NCT01733459 · Dexa Medica Group
2013-03 – 2018-06 · Polycystic Ovary Syndrome (PCOS)
What this study did
Phase 2/3 (7)
Type 2 Diabetes
NCT00362765 · Solvay Pharmaceuticals
2006-10 – 2007-07 · Type 2 Diabetes, Dyslipidemia
What this study did
Other / comorbidity
NCT06975111 · University of Colorado, Denver
2026-03-01 – 2030-10-01 · Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
What this study did
NCT07810998 · Tanta University
2026-09-10 – 2027-05-10 · Poly Cystic Ovary Syndrome
What this study did
NCT07811011 · Tanta University
2026-09-20 – 2027-03-30 · Poly Cystic Ovary Syndrome
What this study did
NCT06125587 · Shengjing Hospital
2023-11-15 – 2024-11-20 · Polycystic Ovary Syndrome, Chiglitazar, Metformin
What this study did
NCT06140108 · SINA Health Education and Welfare Trust
2023-12-15 – 2024-06-30 · Polycystic Ovary Syndrome, Weight Gain, HbA1c
What this study did
NCT03008551 · Hull University Teaching Hospitals NHS Trust
2017-08-18 – 2018-04-02 · Polycystic Ovary Syndrome
What this study did
Phase 2 (23)
Type 2 Diabetes
NCT07929350 · Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
2026-11-20 – 2028-03-15 · Diabetes Mellitus, Type 2
What this study did
NCT05469659 · Shinshu University
2021-09-22 – 2026-10-30 · T2DM (Type 2 Diabetes Mellitus), Metformin, SGLT2-Inhibitors
What this study did
NCT03604419 · PegBio Co., Ltd.
2018-06-13 – 2019-07-23 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT02526524 · Elcelyx Therapeutics, Inc.
2015-09 – 2016-09 · Type 2 Diabetes Mellitus
What this study did
NCT01935804 · King Abdulaziz University
2009-01 – 2014-01 · Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
What this study did
NCT01217073 · Merck Sharp & Dohme LLC
2010-10-08 – 2013-04-01 · Type 2 Diabetes Mellitus
What this study did
NCT00881530 · Boehringer Ingelheim
2009-03 – 2011-05 · Diabetes Mellitus, Type 2
What this study did
NCT01071850 · Astellas Pharma Inc
2010-03-03 – 2011-04-11 · Diabetes Mellitus, Type 2
What this study did
NCT00544518 · Air Force Military Medical University, China
2007-10 – 2008-10 · Type 2 Diabetes
What this study did
NCT00454233 · Astellas Pharma Inc
2007-02 – 2008-06 · Diabetes Mellitus Type 2
What this study did
NCT00479466 · Merck Sharp & Dohme LLC
2007-07 – 2008-05 · Diabetes Mellitus, Type 2
What this study did
NCT00328172 · Boehringer Ingelheim
2006-05 – 2007-08 · Diabetes Mellitus, Type 2
What this study did
NCT02004886 · Merck Sharp & Dohme LLC
2006-08-11 – 2007-02-07 · Type 2 Diabetes Mellitus
What this study did
NCT00263276 · AstraZeneca
2005-12 – 2007-02 · Type 2 Diabetes
What this study did
NCT00481663 · Merck Sharp & Dohme LLC
2003-08-19 – 2006-05-14 · Type II Diabetes Mellitus
What this study did
NCT01511198 · Novo Nordisk A/S
2001-02 – 2001-10 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT04341571 · University of Guadalajara
2019-10-24 – 2027-12 · PreDiabetes, Impaired Glucose Tolerance, Hyperglycemia, Resistance, Insulin
What this study did
NCT05781711 · Tanta University
2023-06-06 – 2024-08-20 · Parkinson Disease
What this study did
NCT03848533 · University of Guadalajara
2019-08-22 – 2021-12 · PreDiabetes
What this study did
NCT02695810 · Steno Diabetes Center Copenhagen
2016-02-24 – 2019-01-13 · Prediabetic State, Obesity
What this study did
NCT02063802 · Laboratorios Silanes S.A. de C.V.
2012-08 – 2014-05 · Obesity
What this study did
NCT01351753 · University of Iowa
2011-03 – 2014-01-09 · Obesity, Metabolic Syndrome X
What this study did
Phase 1/2 (1)
Type 2 Diabetes
NCT04623567 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2021-12-22 – 2024-06-30 · Type2 Diabetes, Dyslipidemias
What this study did
Phase 1 (38)
Type 2 Diabetes
NCT04317703 · LG Chem
2020-08-19 – 2020-09-05 · Type 2 Diabetes
What this study did
NCT00865033 · Sandoz
2005-11 – 2005-11 · Type 2 Diabetes
What this study did
NCT00882882 · Sandoz
2001-06 – 2001-06 · Type II Diabetes
What this study did
Other / comorbidity
NCT06424860 · University of Alberta
2025-11-01 – 2027-12-30 · PCOS, Cardiovascular Disease, Atherosclerotic Cardiovascular Disease, Atherosclerotic Plaque, Cardiac Hypertrophy
What this study did
NCT07459595 · Fatima Tariq
2026-05-01 – 2026-07-31 · Polycystic Ovarian Syndrome (PCOS)
What this study did
NCT07399535 · Jinnah Postgraduate Medical Centre
2025-02-22 – 2026-03-01 · Polycystic Ovarian Syndrome (PCOS), Herbal Medicine, Infertility, Metabolic Disorder
What this study did
NCT05363592 · Celltrion
2022-06-25 – 2022-07-25 · Healthy
What this study did
NCT05363384 · Celltrion
2022-06-11 – 2022-07-12 · Healthy
What this study did
NCT05151146 · Anji Pharma
2021-10-15 – 2022-02-28 · Healthy
What this study did
NCT05124730 · Joint Stock Company "Farmak"
2021-05-21 – 2021-05-29 · Pharmacokinetics
What this study did
NCT04047940 · Eli Lilly and Company
2019-11-29 – 2020-02-18 · Healthy
What this study did
NCT05124717 · Joint Stock Company "Farmak"
2019-06-25 – 2019-07-03 · Pharmacokinetics
What this study did
NCT05123781 · Joint Stock Company "Farmak"
2019-04-03 – 2019-04-17 · Pharmacokinetics
What this study did
NCT05125575 · Joint Stock Company "Farmak"
2019-01-11 – 2019-01-19 · Pharmacokinetics
What this study did
NCT03458208 · Geropharm
2017-02-14 – 2017-03-02 · Bioequivalence
What this study did
NCT02217670 · Disphar International B.V.
est. completion 2016-01 · Comparative Bioavailability
What this study did
NCT02026817 · Hanmi Pharmaceutical Company Limited
2013-12 – 2014-01 · Diabetes Mellitus
What this study did
NCT02011633 · Hanmi Pharmaceutical Company Limited
2013-10 – 2013-12 · Diabetes Mellitus
What this study did
NCT01844531 · Boehringer Ingelheim
2013-04 – 2013-11 · Healthy
What this study did
NCT01929512 · Hanmi Pharmaceutical Company Limited
2013-06 – 2013-08 · Diabetes Mellitus
What this study did
NCT02291510 · Elcelyx Therapeutics, Inc.
2012-10 – 2012-12 · Healthy Subjects
What this study did
NCT01232036 · Asan Medical Center
2010-05 – 2010-10 · Healthy
What this study did
NCT00546741 · AstraZeneca
2007-11 – 2008-02 · Healthy Male and Female Subjects
What this study did
NCT00649948 · Mylan Pharmaceuticals Inc
2004-02 – 2004-06 · Healthy
What this study did
NCT00650234 · Mylan Pharmaceuticals Inc
2004-02 – 2004-03 · Healthy
What this study did
NCT00648518 · Mylan Pharmaceuticals Inc
2003-12 – 2003-12 · Healthy
What this study did
NCT00649350 · Mylan Pharmaceuticals Inc
2003-12 – 2003-12 · Healthy
What this study did
NCT00834613 · Teva Pharmaceuticals USA
2003-08 – 2003-08 · Healthy
What this study did
NCT00834743 · Teva Pharmaceuticals USA
2003-08 – 2003-08 · Healthy
What this study did
NCT00865072 · Actavis Inc.
2003-08 – 2003-08 · Healthy
What this study did
NCT00865852 · Actavis Inc.
2003-08 – 2003-08 · Healthy
What this study did
NCT00648492 · Mylan Pharmaceuticals Inc
2002-10 – 2002-11 · Healthy
What this study did
NCT00650312 · Mylan Pharmaceuticals Inc
2002-10 – 2002-11 · Healthy
What this study did
Phase 4 (53)
Type 2 Diabetes
NCT05366868 · National Center for Global Health and Medicine, Japan
2022-05-26 – 2027-03-31 · Diabetes Mellitus, Type 2
What this study did
NCT06932874 · China National Center for Cardiovascular Diseases
2025-03-04 – 2026-12-31 · Atherosclerotic Heart Disease, Type 2 Diabetes
What this study did
NCT07436182 · Mansoura University
2026-03-01 – 2026-06-01 · Mitochondria, Metformin
What this study did
NCT03982381 · Uppsala University
2019-09-05 – 2026-01-31 · Type 2 Diabetes
What this study did
NCT06846411 · Seoul National University Bundang Hospital
2024-01-01 – 2025-12-31 · Diabetes, Diabetes Mellitus, Type II
What this study did
NCT07541456 · Dr. Zarmina Younes
2025-06-09 – 2025-11-08 · Type 2 Diabetes Mellitus, Hypertension
What this study did
NCT06449235 · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
2024-09 – 2025-06 · Type2diabetes
What this study did
NCT06127433 · Sun Yat-sen University
2023-03-07 – 2024-12-30 · Insulin Pump,Continuous Glucose Monitoring Technology
What this study did
NCT06613750 · Zhibin Xu
2024-06-01 – 2024-07-01 · Type 2 Diabetes Mellitus, Glucotoxicity
What this study did
NCT06145360 · SINA Health Education and Welfare Trust
2023-12-01 – 2024-03-01 · Glucose Metabolism Disorders, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Empagliflozin
What this study did
NCT02911792 · The University of Texas Health Science Center at San Antonio
2016-12-20 – 2023-07-11 · Diabetes Mellitus, Type 2
What this study did
NCT03670043 · West Side Institute for Science and Education
2019-03-19 – 2021-08-15 · Type2 Diabetes Mellitus
What this study did
NCT02686177 · Assistance Publique - Hôpitaux de Paris
2016-05-18 – 2021-05-28 · Type 2 Diabetes
What this study did
NCT04916093 · Beni-Suef University
2019-12-20 – 2020-12-15 · Diabetes Mellitus, Type 2
What this study did
NCT04485845 · Cairo University
2019-11-01 – 2020-09-30 · Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency
What this study did
NCT03359837 · Sanofi
2018-01-20 – 2020-06-29 · Type 2 Diabetes Mellitus
What this study did
NCT03796975 · Xijing Hospital
2018-06-28 – 2019-11-20 · Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Efficacy
What this study did
NCT03377335 · University of Palermo
2017-12-22 – 2019-01 · Type 2 Diabetes Mellitus
What this study did
NCT01717911 · Taipei Veterans General Hospital, Taiwan
2010-09 – 2018-12 · Type 2 Diabetes
What this study did
NCT02853630 · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
2013-12 – 2018-12 · TYpe 2 Diabetes Mellitus
What this study did
NCT02875821 · Yonsei University
2016-04-26 – 2017-06-07 · Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
What this study did
NCT02438397 · Shanghai 6th People's Hospital
2014-12 – 2016-10 · Type 2 Diabetes
What this study did
NCT02503943 · Third Affiliated Hospital of Third Military Medical University
2015-05 – 2016-09 · Type 2 Diabetes, Overweight, Obesity, Masked Hypertension
What this study did
NCT02501850 · Hospital Universitari Vall d'Hebron Research Institute
2014-10 – 2015-10 · Diabetes Mellitus Type 2
What this study did
NCT02129985 · xiaolong zhao
2014-02 – 2015-09 · Type 2 Diabetes
What this study did
NCT01947790 · Xiang Guang-da
2013-09 – 2015-07 · LVM, Type 2 Diabetic Patients With IHD, Endothelial Function
What this study did
NCT02920801 · Shanghai Zhongshan Hospital
2014-12 – 2015-07 · Type 2 Diabetes Mellitus
What this study did
NCT00815399 · University of Campania Luigi Vanvitelli
2007-10 – 2015-04 · Type 2 Diabetes
What this study did
NCT01490918 · The Catholic University of Korea
2012-04 – 2014-09 · Type 2 Diabetes Mellitus
What this study did
NCT02040246 · RenJi Hospital
2009-02 – 2014-01 · Diabetes Mellitus, Type 2
What this study did
NCT00474838 · Kyunghee University Medical Center
2007-04 – 2012-12 · Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity
What this study did
NCT01006590 · AstraZeneca
2009-10 – 2010-12 · Type 2 Diabetes Mellitus
What this study did
NCT01720290 · Novo Nordisk A/S
2002-07-25 – 2003-02-25 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07254572 · National Institute of Cardiology, Warsaw, Poland
2025-07-10 – 2029-08-01 · Coronary Artery Disease, PreDiabetes
What this study did
NCT07342764 · Sultan Qaboos University
2026-09 – 2028-12 · Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
What this study did
NCT06959784 · China-Japan Friendship Hospital
2024-01-01 – 2026-12-31 · Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease
What this study did
NCT07802561 · Nishtar Medical University
2026-04-18 – 2026-10-17 · Gestational Diabetes Mellitus (GDM)
What this study did
NCT06000462 · Oman Ministry of Health
2024-04-22 – 2025-12-30 · Obesity, Dapagliflozin Adverse Reaction, Weight Loss, Effect of Drug
What this study did
NCT05702905 · Peking University First Hospital
2023-05-09 – 2025-06-30 · PCOS (Polycystic Ovary Syndrome), Semaglutide
What this study did
NCT04407650 · King's College London
2021-06-18 – 2025-05-29 · Gestational Diabetes
What this study did
NCT06083935 · Ain Shams University
2023-11-01 – 2024-12-01 · Poly Cystic Ovary Syndrome
What this study did
NCT04508634 · Shanghai 10th People's Hospital
2020-11-01 – 2024-09-30 · Polycystic Ovary Syndrome
What this study did
NCT03708549 · Tianjin Anding Hospital
2021-12-01 – 2023-12-01 · Schizophrenia, Metabolic Syndrome, Berberine, Metformin
What this study did
NCT04593459 · Medical University of Graz
2020-11-03 – 2023-10-16 · Polycystic Ovary Syndrome
What this study did
NCT05663749 · All India Institute of Medical Sciences, Bhubaneswar
2022-09-20 – 2023-08-20 · Metabolic Syndrome, Schizophrenia
What this study did
NCT02981121 · Jeong-taek Woo
2016-11 – 2020-11 · PreDiabetes
What this study did
NCT03352869 · RenJi Hospital
2017-11-28 – 2018-07-31 · Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation
What this study did
NCT01856907 · Woman's
2013-09-28 – 2017-09-28 · Disorder of Glucose Regulation
What this study did
NCT02088034 · Temple University
2013-09 – 2016-02 · Diabetes
What this study did
NCT01960205 · Shandong Provincial Hospital
2013-08 – 2014-12 · Prediabetes
What this study did
Early phase / not applicable (30)
Type 2 Diabetes
NCT06911983 · S.LAB (SOLOWAYS)
2025-07-01 – 2026-03-01 · Diabetes Mellitis
What this study did
NCT06059287 · RenJi Hospital
2023-10-01 – 2025-12-31 · Obesity, Type 2 Diabetes, Sodium-glucose Co-transporter-2 Inhibitor, Myocardial Fibrosis, Magnetic Resonance Imaging
What this study did
NCT05918068 · Al-Rasheed University College
2022-11-01 – 2023-04-01 · Diabetes Mellitus, Type 2
What this study did
NCT05343767 · Natural Wellness Egypt
2018-09-12 – 2021-05-30 · Type2 Diabetes Mellitus
What this study did
NCT01763346 · University of Southern California
2013-06 – 2018-06 · Prediabetes, Type 2 Diabetes, Obesity
What this study did
NCT01303055 · Aichi Gakuin University
2011-02 – 2014-12 · Diabetes Mellitus, Type 2
What this study did
NCT01471275 · Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2011-11 – 2013-12 · Type 2 Diabetes Mellitus ;Obesity,High Triglycerides;TCM
What this study did
NCT01503008 · Proteus Digital Health, Inc.
2012-02 – 2012-08 · Type 2 Diabetes Mellitus
What this study did
NCT00486187 · Dr. Milan Gupta
2006-04 – 2009-06 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07687667 · Peking University Third Hospital
2026-07-07 – 2029-12 · Polycystic Ovary Syndrome (PCOS), Obesity, Infertility, Female
What this study did
NCT07948577 · Jing Ma
2026-12-01 – 2028-10 · Myocardial Fibrosis, Obesity
What this study did
NCT07293325 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-06-02 – 2027-06-02 · Adults With Simple Obesity
What this study did
NCT06318442 · Imperial College London
2024-05-15 – 2027-06-01 · Steroid-Induced Diabetes, Steroid Induced Hyperglycemia
What this study did
NCT07645001 · Riphah International University
2026-07-29 – 2027-06 · Gestational Diabetes
What this study did
NCT07307677 · Mst.Sumyara Khatun
2025-03-11 – 2026-08-10 · PCOS(Insulin Resistant)
What this study did
NCT07931625 · Fauji Foundation Hospital
2024-08-10 – 2026-08-09 · Polycystic Ovarian Syndrome (PCOS)
What this study did
NCT06717087 · RenJi Hospital
2024-12-20 – 2026-06-01 · Polycystic Ovary Syndrome, Metformin, Acupuncture
What this study did
NCT06049186 · Shanghai First Maternity and Infant Hospital
2023-09-15 – 2026-03-31 · Polycystic Ovary Syndrome
What this study did
NCT07061496 · Asad Ullah Jan
2025-08-10 – 2026-03-15 · Pre Diabetic, Pre Diabetes
What this study did
NCT05966792 · Shanghai 10th People's Hospital
2023-11-10 – 2025-06-30 · Polycystic Ovary Syndrome
What this study did
NCT02521753 · Coordinación de Investigación en Salud, Mexico
2015-08 – 2025-03 · Polycystic Ovary Syndrome, Obesity
What this study did
NCT04892186 · University of Sao Paulo General Hospital
2021-03-26 – 2023-10-20 · Polycystic Ovary Syndrome, Resistance, Insulin, Glucose Intolerance
What this study did
NCT05386706 · Shanghai 10th People's Hospital
2022-06-21 – 2023-09-01 · Polycystic Ovary Syndrome
What this study did
NCT03375580 · The First Affiliated Hospital of Guangdong Pharmaceutical University
2017-12-31 – 2019-12-31 · Nonalcoholic Fatty Liver Disease
What this study did
NCT01302743 · Mike O'Callaghan Military Hospital
2010-11 – 2016-12 · Diabetes
What this study did
NCT01679574 · Assiut University
2009-01 – 2012-01 · Polycystic Ovary Syndrome
What this study did
NCT00536211 · University of Kansas Medical Center
2009-06 – 2011-12 · Metabolic Syndrome X, Insulin Resistance, Hypertension, Hypercholesterolemia, Obesity
What this study did
NCT01677260 · Dexa Medica Group
2009-10 – 2010-01 · Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose
What this study did
NCT01008046 · Mansoura University
2007-04 – 2009-06 · Polycystic Ovary Syndrome
What this study did
NCT00911313 · Mansoura University
2006-06 – 2009-01 · Polycystic Ovary Syndrome
What this study did
Studied as part of a combination product (2)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Type 2 Diabetes
NCT05054842 · Jiangsu HengRui Medicine Co., Ltd.
2021-12-06 – 2023-12 · Type 2 Diabetes
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT05415644 · Shandong Suncadia Medicine Co., Ltd.
2022-07-05 – 2022-08-08 · Type 2 Diabetes Mellitus
What this study did
Appears in other studies (123)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (66)
Type 2 Diabetes
NCT04029480 · Merck Sharp & Dohme LLC
2019-10-08 – 2025-04-11 · Type 2 Diabetes Mellitus
What this study did
NCT05326490 · PegBio Co., Ltd.
2022-05-30 – 2024-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT05416580 · University of Banja Luka
2022-09-12 – 2024-04 · Diabetes Mellitus, Type 2
What this study did
NCT05226897 · Yooyoung Pharmaceutical Co., Ltd.
2021-07-12 – 2023-06-26 · Type 2 Diabetes
What this study did
NCT03429543 · Boehringer Ingelheim
2018-03-20 – 2023-05-31 · Diabetes Mellitus, Type 2
What this study did
NCT04807348 · Chipscreen Biosciences, Ltd.
2021-07-06 – 2023-02-10 · Type 2 Diabetes
What this study did
NCT03851432 · Sihuan Pharmaceutical Holdings Group Ltd.
2019-06-30 – 2021-12-31 · Diabetes Mellitus, Type 2
What this study did
NCT04218734 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2020-01-14 – 2021-06-03 · Type 2 Diabetes Mellitus
What this study did
NCT03608358 · AstraZeneca
2019-02-27 – 2020-08-04 · Type 2 Diabetes Mellitus
What this study did
NCT01541215 · Novo Nordisk A/S
2012-11-13 – 2020-05-20 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT03332771 · Lexicon Pharmaceuticals
2017-12-01 – 2019-09-06 · Type 2 Diabetes Mellitus
What this study did
NCT03349684 · Bayer
2018-03-05 – 2019-08-21 · Diabetes Mellitus, Type 2
What this study did
NCT03419624 · Universitätsklinikum Hamburg-Eppendorf
2018-02-19 – 2019-08-05 · Obesity, Diabetes Mellitus, Type 2
What this study did
NCT02924064 · Tanabe Pharma Corporation
2016-09 – 2018-09-25 · Type 2 Diabetes Mellitus
What this study did
NCT02791490 · Merck Sharp & Dohme LLC
2016-06-16 – 2018-02-01 · Type 2 Diabetes Mellitus
What this study did
NCT02738879 · Merck Sharp & Dohme LLC
2016-05-09 – 2018-01-30 · Type 2 Diabetes Mellitus
What this study did
NCT02630706 · Merck Sharp & Dohme LLC
2015-12-16 – 2017-12-27 · Type 2 Diabetes Mellitus
What this study did
NCT02033889 · Merck Sharp & Dohme LLC
2013-12-13 – 2017-08-03 · Type 2 Diabetes Mellitus
What this study did
NCT02477969 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2014-02-27 – 2017-06 · Type 2 Diabetes Mellitus
What this study did
NCT02597049 · Eli Lilly and Company
2015-11 – 2017-02 · Type 2 Diabetes Mellitus
What this study did
NCT02152371 · Eli Lilly and Company
2014-05 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01691846 · Hoffmann-La Roche
2012-10 – 2013-09 · Diabetes Mellitus Type 2
What this study did
NCT01871415 · Hoffmann-La Roche
2013-05 – 2013-08 · Diabetes Mellitus Type 2
What this study did
NCT01462266 · Merck Sharp & Dohme LLC
2012-01-13 – 2013-06-07 · Type 2 Diabetes Mellitus
What this study did
NCT00838903 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT00839527 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01505426 · Astellas Pharma Inc
2011-11-28 – 2013-01-14 · Type II Diabetes Mellitus
What this study did
NCT01064687 · Eli Lilly and Company
2010-02 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT01106625 · Janssen Research & Development, LLC
2010-05 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT00855166 · AstraZeneca
2009-02 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
NCT01217892 · AstraZeneca
2010-11 – 2011-08 · Type 2 Diabetes
What this study did
NCT00763815 · Sanofi
2008-09 – 2011-06 · Diabetes Mellitus Type 2
What this study did
NCT00754988 · Hoffmann-La Roche
2008-10 – 2011-03 · Diabetes Mellitus Type 2
What this study did
NCT00715624 · Sanofi
2008-07 – 2011-02 · Diabetes Mellitus, Type 2
What this study did
NCT00713830 · Sanofi
2008-07 – 2011-01 · Diabetes Mellitus, Type 2
What this study did
NCT00885352 · Merck Sharp & Dohme LLC
2009-04-15 – 2010-11-10 · Type 2 Diabetes Mellitus
What this study did
NCT00960076 · AstraZeneca
2009-08 – 2010-10 · Type 2 Diabetes
What this study did
Phase 2/3 (3)
Type 2 Diabetes
NCT00734474 · Eli Lilly and Company
2008-08 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT00860288 · Novartis Pharmaceuticals
2009-02 – 2011-03 · Diabetes Mellitus, Type 2
What this study did
NCT00900146 · Novartis
2009-04 – 2010-11 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (26)
Type 2 Diabetes
NCT02597101 · Nick Giannoukakis, PhD
2015-11 – 2019-06-15 · Type 2 Diabetes Mellitus, Insulin Resistance
What this study did
NCT03444584 · MedImmune LLC
2018-05-08 – 2018-12-06 · Type 2 Diabetes Mellitus
What this study did
NCT02973321 · Sanofi
2016-12-02 – 2017-12-27 · Type 2 Diabetes Mellitus
What this study did
NCT02492763 · Merck Sharp & Dohme LLC
2015-07-27 – 2017-04-18 · Type II Diabetes Mellitus
What this study did
NCT02434744 · Response Pharmaceuticals
2015-04 – 2016-03 · Type 2 Diabetes Mellitus
What this study did
NCT02119819 · OPKO Health, Inc.
2014-04 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT02205528 · Novo Nordisk A/S
2014-08-18 – 2015-09-15 · Diabetes, Diabetes Mellitus Type 2
What this study did
NCT02111096 · Eli Lilly and Company
2014-04 – 2015-09 · Diabetes Mellitus, Type 2
What this study did
NCT01918865 · Ionis Pharmaceuticals, Inc.
2013-08 – 2015-02 · Type 2 Diabetes Mellitus, Obese
What this study did
NCT02202161 · GlaxoSmithKline
2014-08-27 – 2015-01-30 · Diabetes Mellitus, Type 2
What this study did
NCT02091362 · Eli Lilly and Company
2014-03 – 2015-01 · Type 2 Diabetes Mellitus
What this study did
NCT01729403 · Hoffmann-La Roche
2012-12 – 2013-09 · Diabetes Mellitus Type 2
What this study did
NCT01340664 · Janssen Research & Development, LLC
2011-07 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01059825 · Merck Sharp & Dohme LLC
2010-02-24 – 2011-01-20 · Diabetes Mellitus, Type 2
What this study did
NCT01046422 · Bristol-Myers Squibb
2010-05 – 2011-01 · Diabetes Type 2
What this study did
NCT00605475 · Novartis
2007-12 – 2010-09 · Type 2 Diabetes Mellitus
What this study did
NCT00767000 · Merck Sharp & Dohme LLC
2008-10 – 2010-06 · Diabetes Mellitus, Type 2
What this study did
NCT00901979 · Novartis Pharmaceuticals
2009-04 – 2010-06 · Type 2 Diabetes Mellitus
What this study did
NCT00814372 · Gilead Sciences
2008-12 – 2010-02 · Type 2 Diabetes Mellitus
What this study did
NCT00420511 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2007-01 – 2009-09 · Type 2 Diabetes Mellitus
What this study did
NCT00698789 · Incyte Corporation
2008-05 – 2009-06 · Type 2 Diabetes
What this study did
NCT00672386 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2007-12 – 2008-09 · Diabetes Mellitus, Type 2, Diabetes Mellitus, Endocrine System Diseases, Nutritional and Metabolic Diseases
What this study did
NCT00266253 · Hoffmann-La Roche
2005-11 – 2007-03 · Diabetes Mellitus Type 2
What this study did
NCT00111631 · Hoffmann-La Roche
2005-05 – 2006-10 · Diabetes Mellitus Type 2
What this study did
Other / comorbidity
NCT07182526 · Al-Mustansiriyah University
2025-09-20 – 2026-05-01 · PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
What this study did
NCT00362440 · Beth Israel Deaconess Medical Center
2006-08 – 2011-06 · HIV Lipodystrophy
What this study did
Phase 1/2 (2)
Type 2 Diabetes
NCT02960659 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2017-05-09 – 2022-05-20 · Type 2 Diabetes
What this study did
NCT02020616 · Eli Lilly and Company
2013-12 – 2015-02 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (8)
Type 2 Diabetes
NCT02956044 · Theracos
2016-11 – 2017-03 · Type2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07875842 · InventisBio Co., Ltd
2026-09-16 – 2026-12-31 · Healthy Subjects
What this study did
NCT07446400 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-03-31 – 2026-11-07 · Healthy Volunteers
What this study did
NCT07362030 · Guangdong Raynovent Biotech Co., Ltd
2025-04-14 – 2026-03-30 · Obesity
What this study did
NCT06793943 · Takeda
2025-01-23 – 2025-03-30 · Healthy Volunteers
What this study did
NCT04621669 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-08 – 2021-09-08 · Drug-drug Interaction,SHR3680
What this study did
NCT04064073 · Daewoong Pharmaceutical Co. LTD.
2019-08-14 – 2019-11-20 · Healthy
What this study did
NCT02574845 · Boehringer Ingelheim
2015-10-12 – 2015-12-14 · Healthy
What this study did
Phase 4 (11)
Type 2 Diabetes
NCT06762223 · Xiqiao Zhou
2024-12-31 – 2026-12-31 · Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus
What this study did
NCT05942963 · Jinnah Postgraduate Medical Centre
2023-10 – 2024-04 · Non-Alcoholic Fatty Liver Disease, Type2diabetes
What this study did
NCT02235298 · University of Miami
2015-09 – 2020-09-10 · Type 2 Diabetes
What this study did
NCT02014740 · University of Miami
2014-03 – 2017-03 · Type 2 Diabetes, Overweight, Obesity
What this study did
NCT02002221 · Novartis Pharmaceuticals
2013-12 – 2015-02 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01541956 · Novartis Pharmaceuticals
2012-02 – 2013-12 · Type 2 Diabetes
What this study did
NCT00951899 · Mayo Clinic
2009-08 – 2012-12 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT06256289 · Ping Li,MD
2024-03-31 – 2025-04-30 · Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
What this study did
NCT03603080 · Hartford Hospital
2019-03-01 – 2022-09-01 · Obesity
What this study did
NCT03819127 · University of Catania
2015-01 – 2016-09 · Mild Cognitive Impairment
What this study did
NCT00953355 · University Magna Graecia
2004-01 – 2007-05 · Polycystic Ovary Syndrome, Anovulation
What this study did
Early phase / not applicable (7)
Type 2 Diabetes
NCT02443922 · Foundation for the National Institutes of Health
2015-06 – 2015-12 · Type 2 Diabetes
What this study did
NCT00577590 · Washington University School of Medicine
2003-10 – 2012-09 · Diabetes Mellitus, Type II
What this study did
NCT01033773 · Medstar Health Research Institute
2007-09 – 2009-01 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06775093 · Peking University Third Hospital
2025-03-01 – 2027-12-31 · Polycystic Ovary Syndrome, Obesity, Infertility, Female
What this study did
NCT06666933 · RenJi Hospital
2024-11-01 – 2026-07 · PCOS, Glucose Metabolism Disorder, IVF Outcome
What this study did
NCT06515652 · Hamdard University
2023-09-01 – 2024-08-30 · Metabolic Syndrome
What this study did
NCT02524821 · Gelesis, Inc.
2015-09 – 2015-12 · Healthy Overweight Obese
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Metformin (Glucophage): this drugApprovedSmall moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Retagliptin / Metformin (Ruilintang)Phase 1Small moleculeDPP-4, AMPKPartial signalNo reviewed efficacy summary in this indication

Large race: only the 61 furthest-along competitors are listed; 89 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(137 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Glucophage (metformin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (20)
November 2026 (2)
Phase 3Steinert's Disease, Myotonic Dystrophy 1, MetforminRecruiting
Est. primary completion 2026-11 · NCT05532813 · CT.gov ↗
What to watch
Phase 1Healthy Adult ParticipantsNot yet recruiting
Est. primary completion 2026-11-30 · NCT07796191 · CT.gov ↗
What to watch
December 2026 (18)
Early phase / not applicableType 2 DiabetesActive not recruiting
Est. primary completion 2026-12 · NCT02087826 · CT.gov ↗
What to watch
Phase 4Atrial FibrillationActive not recruiting
Est. primary completion 2026-12 · NCT03603912 · CT.gov ↗
What to watch
Phase 2Inflammatory Bowel DiseasesRecruiting
Est. primary completion 2026-12 · NCT05574387 · CT.gov ↗
What to watch
Phase 2Oesophageal Adenocarcinoma, Tumor MicroenvironmentRecruiting
Est. primary completion 2026-12 · NCT06687876 · CT.gov ↗
What to watch
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2026-12 · NCT07093476 · CT.gov ↗
What to watch
Phase 1Drug Drug Interaction (DDI), Pharmacokinetics and PharmacodynamicsRecruiting
Est. primary completion 2026-12 · NCT07785934 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesEnrolling by invitation
Est. primary completion 2026-12-01 · NCT06846138 · CT.gov ↗
What to watch
Early phase / not applicableMelasma (Facial Melasma), MelasmaNot yet recruiting
Est. primary completion 2026-12-01 · NCT07485777 · CT.gov ↗
What to watch
Early phase / not applicableMelasmaNot yet recruiting
Est. primary completion 2026-12-01 · NCT07495748 · CT.gov ↗
What to watch
Phase 1Overweight, ObesityNot yet recruiting
Est. primary completion 2026-12-01 · NCT07502001 · CT.gov ↗
What to watch
Early phase / not applicablePolycystic Ovarian Syndrome (PCOS)Active not recruiting
Est. primary completion 2026-12-03 · NCT07604779 · CT.gov ↗
What to watch
Phase 1Overweight,ObesityActive not recruiting
Est. primary completion 2026-12-05 · NCT07550816 · CT.gov ↗
What to watch
Phase 1Advanced Pancreatic Cancer, Advanced Solid TumorActive not recruiting
Est. primary completion 2026-12-30 · NCT03889795 · CT.gov ↗
What to watch
Phase 4Polycystic Ovary Syndrome, MetforminActive not recruiting
Est. primary completion 2026-12-30 · NCT05680805 · CT.gov ↗
What to watch
Phase 1Breast Cancer, Solid TumorActive not recruiting
Est. primary completion 2026-12-31 · NCT03006172 · CT.gov ↗
What to watch
Early phase / not applicableMetformin, Prediabetes, In-Vitro FertilizationRecruiting
Est. primary completion 2026-12-31 · NCT06064669 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2026-12-31 · NCT06120881 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2026-12-31 · NCT07165158 · CT.gov ↗
What to watch
2027 (69)
January 2027 (5)
Phase 2COVID-19Recruiting
Est. primary completion 2027-01 · NCT05041907 · CT.gov ↗
What to watch
Phase 2Pelvic Pain, EndometriosisActive not recruiting
Est. primary completion 2027-01 · NCT06611501 · CT.gov ↗
What to watch
Phase 2Epidermal Melasma, Facial HyperpigmentationNot yet recruiting
Est. primary completion 2027-01-15 · NCT07779811 · CT.gov ↗
What to watch
Phase 1Type 2 DiabetesRecruiting
Est. primary completion 2027-01-29 · NCT07024823 · CT.gov ↗
What to watch
Early phase / not applicableDefectRecruiting
Est. primary completion 2027-01-30 · NCT05205317 · CT.gov ↗
What to watch
February 2027 (8)
Phase 3Obesity, Childhood, Insulin ResistanceRecruiting
Est. primary completion 2027-02 · NCT04578652 · CT.gov ↗
What to watch
Early phase / not applicableStress Resilience, Blood-Brain Barrier Integrity, Mental HealthNot yet recruiting
Est. primary completion 2027-02 · NCT06965868 · CT.gov ↗
What to watch
Phase 2Malignant Brain NeoplasmActive not recruiting
Est. primary completion 2027-02-01 · NCT06377696 · CT.gov ↗
What to watch
Phase 4Parkinsons Disease (PD)Not yet recruiting
Est. primary completion 2027-02-01 · NCT07806019 · CT.gov ↗
What to watch
Early phase / not applicableControlled Type 2 Diabetic Patients With PeriodontitisNot yet recruiting
Est. primary completion 2027-02-07 · NCT07753317 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesRecruiting
Est. primary completion 2027-02-28 · NCT02969798 · CT.gov ↗
What to watch
Phase 3Intermittent ClaudicationRecruiting
Est. primary completion 2027-02-28 · NCT05132439 · CT.gov ↗
What to watch
Phase 2Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary-progressive Multiple SclerosisActive not recruiting
Est. primary completion 2027-02-28 · NCT05893225 · CT.gov ↗
What to watch
March 2027 (12)
Phase 1/2Multiple Sclerosis (MS)Recruiting
Est. primary completion 2027-03 · NCT04121468 · CT.gov ↗
What to watch
Phase 1HealthyRecruiting
Est. primary completion 2027-03 · NCT07339722 · CT.gov ↗
What to watch
Phase 1TP53 Y220C Mutation, Advanced Solid TumorsRecruiting
Est. primary completion 2027-03 · NCT07372625 · CT.gov ↗
What to watch
Phase 1Steatohepatitis, Nonalcoholic, Osteo ArthritisNot yet recruiting
Est. primary completion 2027-03 · NCT07873229 · CT.gov ↗
What to watch
Phase 1Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin SensitivityRecruiting
Est. primary completion 2027-03-01 · NCT05065372 · CT.gov ↗
What to watch
Phase 4Intellectual Disability, Developmental Disability, ObesityRecruiting
Est. primary completion 2027-03-01 · NCT05744479 · CT.gov ↗
What to watch
Early phase / not applicableDental Implant, StabilityRecruiting
Est. primary completion 2027-03-09 · NCT07497568 · CT.gov ↗
What to watch
Phase 1HIV InfectionsNot yet recruiting
Est. primary completion 2027-03-12 · NCT07939594 · CT.gov ↗
What to watch
Phase 2Cirrhosis, Portal Hypertension Related to CirrhosisRecruiting
Est. primary completion 2027-03-30 · NCT06687265 · CT.gov ↗
What to watch
Phase 2Fibromyalgia SyndromeRecruiting
Est. primary completion 2027-03-31 · NCT05900466 · CT.gov ↗
What to watch
Phase 3Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index &gt;30 kg/m2)Recruiting
Est. primary completion 2027-03-31 · NCT07297290 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-03-31 · NCT07442006 · CT.gov ↗
What to watch
May 2027 (3)
Phase 2Weight Loss, Gestational Diabetes Mellitus in Pregnancy, Postpartum CareActive not recruiting
Est. primary completion 2027-05 · NCT06948825 · CT.gov ↗
What to watch
Phase 2Alveolar CleftNot yet recruiting
Est. primary completion 2027-05-01 · NCT07536620 · CT.gov ↗
What to watch
Phase 1/2Prostate Cancer Recurrent, Solid Tumor, AdultRecruiting
Est. primary completion 2027-05-21 · NCT05036226 · CT.gov ↗
What to watch
June 2027 (4)
Early phase / not applicableMales, Females, Sedentary, Metformin, PrediabetesRecruiting
Est. primary completion 2027-06-01 · NCT07131384 · CT.gov ↗
What to watch
Early phase / not applicableDepression, Depressive Disorder, Overweight or Obesity, Depressive SymptomsRecruiting
Est. primary completion 2027-06-11 · NCT07654179 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-06-30 · NCT07173712 · CT.gov ↗
What to watch
Phase 4Melasma (Facial Melasma)Enrolling by invitation
Est. primary completion 2027-06-30 · NCT07696806 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Osteosarcoma, Ewing SarcomaRecruiting
Est. primary completion 2027-07 · NCT04758000 · CT.gov ↗
What to watch
Phase 1Pre-Diabetes, Weight, Body, Cardiovascular DiseasesRecruiting
Est. primary completion 2027-07 · NCT06446531 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2027-07-07 · NCT07098299 · CT.gov ↗
What to watch
Phase 2Oral LeukoplakiaRecruiting
Est. primary completion 2027-07-30 · NCT05727761 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1Acanthosis NigricansNot yet recruiting
Est. primary completion 2027-08-10 · NCT07760181 · CT.gov ↗
What to watch
Phase 1DNMT3A Gene MutationRecruiting
Est. primary completion 2027-08-30 · NCT07188740 · CT.gov ↗
What to watch
September 2027 (9)
Phase 2Oral LeukoplakiaRecruiting
Est. primary completion 2027-09 · NCT07387900 · CT.gov ↗
What to watch
Early phase / not applicablePCOS (Polycystic Ovary Syndrome), Insulin Resistance, Obesity (BMI>30)Recruiting
Est. primary completion 2027-09 · NCT07770711 · CT.gov ↗
What to watch
Phase 2Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-09-01 · NCT07139405 · CT.gov ↗
What to watch
Early phase / not applicableObesity, Weight LossActive not recruiting
Est. primary completion 2027-09-15 · NCT04194424 · CT.gov ↗
What to watch
Phase 3Type 1 Diabetes, Peripheral Arterial CalcificationActive not recruiting
Est. primary completion 2027-09-29 · NCT04583462 · CT.gov ↗
What to watch
Phase 2Infertility, FemaleNot yet recruiting
Est. primary completion 2027-09-30 · NCT06012682 · CT.gov ↗
What to watch
Phase 4Psychosis, Cannabis UseNot yet recruiting
Est. primary completion 2027-09-30 · NCT07001878 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-09-30 · NCT07323381 · CT.gov ↗
What to watch
Early phase / not applicableJaw Cysts, Metformin, Inflammatory Cyst, Cyst Enucleation, Odontogenic CystsNot yet recruiting
Est. primary completion 2027-09-30 · NCT07867236 · CT.gov ↗
What to watch
October 2027 (4)
Phase 4Plasminogen Activator Inhibitor-1 Deficiency, Cardiac FibrosisActive not recruiting
Est. primary completion 2027-10 · NCT05317806 · CT.gov ↗
What to watch
Phase 1Castration Sensitive Prostate CancerRecruiting
Est. primary completion 2027-10 · NCT06044025 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2027-10-10 · NCT07778719 · CT.gov ↗
What to watch
Phase 4NIDDM, ObesityActive not recruiting
Est. primary completion 2027-10-30 · NCT05949008 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1/2Focal Segmental GlomerulosclerosisRecruiting
Est. primary completion 2027-11 · NCT06090227 · CT.gov ↗
What to watch
Phase 2GoutRecruiting
Est. primary completion 2027-11-20 · NCT06924658 · CT.gov ↗
What to watch
Phase 3Medulloblastoma, Childhood, Cognitive ImpairmentRecruiting
Est. primary completion 2027-11-30 · NCT05230758 · CT.gov ↗
What to watch
December 2027 (15)
Phase 3Cognitive DeclineActive not recruiting
Est. primary completion 2027-12 · NCT04511416 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-12 · NCT06682351 · CT.gov ↗
What to watch
Phase 2Multiple SclerosisRecruiting
Est. primary completion 2027-12-01 · NCT06463743 · CT.gov ↗
What to watch
Phase 3Post COVID ConditionEnrolling by invitation
Est. primary completion 2027-12-01 · NCT07280572 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-12-01 · NCT07939750 · CT.gov ↗
What to watch
Phase 2Cystic Fibrosis-related Diabetes, Cystic FibrosisRecruiting
Est. primary completion 2027-12-30 · NCT04530383 · CT.gov ↗
What to watch
Phase 2GlaucomaRecruiting
Est. primary completion 2027-12-31 · NCT05426044 · CT.gov ↗
What to watch
Phase 1Gestational DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT05917587 · CT.gov ↗
What to watch
Phase 3PreeclampsiaRecruiting
Est. primary completion 2027-12-31 · NCT06033131 · CT.gov ↗
What to watch
Phase 3SchizophreniaRecruiting
Est. primary completion 2027-12-31 · NCT07045142 · CT.gov ↗
What to watch
Phase 3Polycystic Ovary Syndrome (PCOS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07120815 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07244003 · CT.gov ↗
What to watch
Early phase / not applicableLatent Autoimmune Diabetes in Adults (LADA)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07460336 · CT.gov ↗
What to watch
Phase 1StrokeRecruiting
Est. primary completion 2027-12-31 · NCT07588932 · CT.gov ↗
What to watch
Phase 4Type 2 DiabetesRecruiting
Est. primary completion 2027-12-31 · NCT07771010 · CT.gov ↗
What to watch
2028 (21)
January 2028 (3)
Phase 1Hypoxic-Ischemic Encephalopathy, HIE, Neurodevelopment, Infant DevelopmentEnrolling by invitation
Est. primary completion 2028-01-01 · NCT06429007 · CT.gov ↗
What to watch
Phase 1Advanced MelanomaActive not recruiting
Est. primary completion 2028-01-31 · NCT03311308 · CT.gov ↗
What to watch
Phase 3Thyroid CancerRecruiting
Est. primary completion 2028-01-31 · NCT05468554 · CT.gov ↗
What to watch
February 2028 (3)
Phase 2Appendiceal Mucinous Neoplasm, Pseudomyxoma PeritoneiRecruiting
Est. primary completion 2028-02 · NCT07693452 · CT.gov ↗
What to watch
Early phase / not applicableType 2 DiabetesNot yet recruiting
Est. primary completion 2028-02 · NCT07768280 · CT.gov ↗
What to watch
Phase 1/2ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal DegenerationActive not recruiting
Est. primary completion 2028-02-02 · NCT04545736 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2BurnsNot yet recruiting
Est. primary completion 2028-03 · NCT04530058 · CT.gov ↗
What to watch
April 2028 (2)
Phase 1Osteoarthritis (OA) of the KneeRecruiting
Est. primary completion 2028-04-17 · NCT07065591 · CT.gov ↗
What to watch
Phase 2Posterior Fossa Ependymal TumorRecruiting
Est. primary completion 2028-04-30 · NCT07226453 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Glioblastoma, IDH-wildtypeRecruiting
Est. primary completion 2028-05 · NCT04945148 · CT.gov ↗
What to watch
Early phase / not applicableSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite AthletesEnrolling by invitation
Est. primary completion 2028-05-01 · NCT07568574 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Abdominal Aortic AneurysmRecruiting
Est. primary completion 2028-06-30 · NCT04500756 · CT.gov ↗
What to watch
Phase 2Cognitive Decline, Cognitive Impairment, DementiaActive not recruiting
Est. primary completion 2028-06-30 · NCT05109169 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2Heart Failure, Left Ventricular Assist DeviceRecruiting
Est. primary completion 2028-07 · NCT07666698 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Endometrial CancerRecruiting
Est. primary completion 2028-08-01 · NCT03675893 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1Bronchopulmonary Dysplasia (BPD)Recruiting
Est. primary completion 2028-09-01 · NCT07120971 · CT.gov ↗
What to watch
Phase 3Empgliflozin Cardioprotective EffectNot yet recruiting
Est. primary completion 2028-09-30 · NCT07815808 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Sarcoma Metastatic, Sarcoma, Soft TissueRecruiting
Est. primary completion 2028-10 · NCT07291297 · CT.gov ↗
What to watch
November 2028 (1)
Phase 4Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIVRecruiting
Est. primary completion 2028-11-30 · NCT06829238 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Primary Sclerosing Cholangitis (PSC)Not yet recruiting
Est. primary completion 2028-12 · NCT07898839 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer MetastaticRecruiting
Est. primary completion 2028-12-01 · NCT06030622 · CT.gov ↗
What to watch
2029 (11)
January 2029 (1)
Phase 2Endometrioid Endometrial Cancer, Atypical Endometrial HyperplasiaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07890064 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1Chronic Obstructive Pulmonary Disease (COPD)Not yet recruiting
Est. primary completion 2029-02-01 · NCT07275359 · CT.gov ↗
What to watch
March 2029 (2)
Phase 3Idiopathic Pulmonary FibrosisNot yet recruiting
Est. primary completion 2029-03-15 · NCT07520110 · CT.gov ↗
What to watch
Phase 3Pre-Eclampsia Onset Less Than 37 Weeks, Pre-Eclampsia, Pre-Eclampsia; Complicating Pregnancy, Pre-Eclampsia as Antepartum Condition …Recruiting
Est. primary completion 2029-03-19 · NCT06452498 · CT.gov ↗
What to watch
April 2029 (1)
Early phase / not applicableDiabete MellitusRecruiting
Est. primary completion 2029-04-30 · NCT07589387 · CT.gov ↗
What to watch
May 2029 (3)
Phase 3COPDNot yet recruiting
Est. primary completion 2029-05-01 · NCT06999343 · CT.gov ↗
What to watch
Phase 4PCOS, Obesity, InfertilityRecruiting
Est. primary completion 2029-05-30 · NCT06742710 · CT.gov ↗
What to watch
Phase 1Muscle Atrophy or WeaknessRecruiting
Est. primary completion 2029-05-31 · NCT06185179 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Prediabetic State, Atherosclerosis, MetforminRecruiting
Est. primary completion 2029-09-28 · NCT02915198 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL TearRecruiting
Est. primary completion 2029-12 · NCT06096259 · CT.gov ↗
What to watch
Phase 4Gestational Diabetes Mellitus, Pregnancy, High RiskRecruiting
Est. primary completion 2029-12 · NCT06445946 · CT.gov ↗
What to watch
2030 (7)
July 2030 (1)
Phase 1/2Breast Cancer, Solid Tumors, AdultRecruiting
Est. primary completion 2030-07 · NCT05768139 · CT.gov ↗
What to watch
September 2030 (2)
Phase 1Intertrochanteric Femur Fracture, Muscle AtrophyEnrolling by invitation
Est. primary completion 2030-09 · NCT07179042 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN)Recruiting
Est. primary completion 2030-10-14 · NCT07901959 · CT.gov ↗
What to watch
Phase 3Acute Ischemic StrokeNot yet recruiting
Est. primary completion 2030-10-30 · NCT07899307 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 3Autosomal Dominant Polycystic Kidney DiseaseRecruiting
Est. primary completion 2030-12 · NCT04939935 · CT.gov ↗
What to watch
2031 (6)
January 2031 (1)
Phase 3TuberculosisNot yet recruiting
Est. primary completion 2031-01 · NCT07136987 · CT.gov ↗
What to watch
March 2031 (2)
Phase 1/2Hyperemesis GravidarumRecruiting
Est. primary completion 2031-03 · NCT07129473 · CT.gov ↗
What to watch
Phase 3Alzheimer&#39;s Disease (AD), Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer Disease DementiaRecruiting
Est. primary completion 2031-03 · NCT07724132 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2031-06-16 · NCT06763328 · CT.gov ↗
What to watch
October 2031 (1)
Phase 1Atrophy, Inflammation, Weakness, MuscleNot yet recruiting
Est. primary completion 2031-10-01 · NCT07699367 · CT.gov ↗
What to watch
November 2031 (1)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2031-11 · NCT04536805 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 2Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma …Recruiting
Est. primary completion 2032-04-30 · NCT04114136 · CT.gov ↗
What to watch
2035 (1)
October 2035 (1)
Phase 1Prostate CancerActive not recruiting
Est. primary completion 2035-10-20 · NCT05515978 · CT.gov ↗
What to watch
2043 (1)
December 2043 (1)
Phase 3Gestational Diabetes, Insulin ResistanceRecruiting
Est. primary completion 2043-12 · NCT02947503 · CT.gov ↗
What to watch

See the full readout calendar ↗